Login / Signup

Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study.

Sanne M H ZweijpfenningStephan E P KopsMartin J BoereeSaskia KuipersJakko van IngenWouter HoefslootCecile Magis-Escurra
Published in: ERJ open research (2021)
Addition of intravenous amikacin and clofazimine to recommended rifamycin-ethambutol-macrolide regimens yields favourable outcomes in severe M. avium complex pulmonary disease (MAC-PD). This five-drug regimen should be considered in select MAC-PD patients. https://bit.ly/30dxdRj.
Keyphrases
  • end stage renal disease
  • pulmonary hypertension
  • ejection fraction
  • newly diagnosed
  • early onset
  • chronic kidney disease
  • mycobacterium tuberculosis
  • prognostic factors
  • peritoneal dialysis
  • type diabetes